RareGen
Liquidia Corporation is dedicated to developing best-in-class therapies for rare cardiopulmonary diseases such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). They focus on innovative drug delivery to help patients breathe easier and live longer, utilizing proprietary formulations and PRINT® technology to enhance the efficacy, tolerability, and convenience of medicines. The company is committed to improving patient outcomes through a pipeline of innovative therapies and supporting patients with resources and clinical trials.
Industries
Nr. of Employees
small (1-50)
Products
Clinical- and commercial-stage inhaled treprostinil-class therapies (pulmonary delivery)
A pipeline of inhalation therapies targeting PAH and PH-ILD, spanning clinical-stage programs and commercially available inhaled prostacyclin-class treatments.
Clinical- and commercial-stage inhaled treprostinil-class therapies (pulmonary delivery)
A pipeline of inhalation therapies targeting PAH and PH-ILD, spanning clinical-stage programs and commercially available inhaled prostacyclin-class treatments.
Services
Design and execution of clinical development programs across phases for pulmonary indications, including pivotal investigator-led studies.
Process development, scale-up, technology transfer and process validation services for drug and drug–device combination products intended for pulmonary delivery.
Regulatory planning and coordination for global submissions, including preparation of documentation to support regulatory filings.
Design and optimization of particle properties and inhalation delivery approaches using imprinting-based manufacturing concepts to improve lung deposition and tolerability.
Commercial planning, market access strategy and launch support to maximize product uptake and reimbursement for specialty pulmonary therapies.
Design and execution of clinical development programs across phases for pulmonary indications, including pivotal investigator-led studies.
Process development, scale-up, technology transfer and process validation services for drug and drug–device combination products intended for pulmonary delivery.
Regulatory planning and coordination for global submissions, including preparation of documentation to support regulatory filings.
Design and optimization of particle properties and inhalation delivery approaches using imprinting-based manufacturing concepts to improve lung deposition and tolerability.
Commercial planning, market access strategy and launch support to maximize product uptake and reimbursement for specialty pulmonary therapies.
Expertise Areas
- Pulmonary arterial hypertension (PAH) and PH-ILD therapeutics
- Inhaled drug delivery
- Clinical trial management and execution
- Drug–device combination product development
Key Technologies
- Precision particle engineering (imprint-based fabrication)
- Aerosol / inhalation delivery systems
- Drug–device combination platforms
- Pulmonary formulation technologies